Huntington Disease: all 290 studies

Page 2 of 3. Open to participants first (49), then studies with results posted, then the rest; newest registration first within each.

• Study of Memantine to Treat Huntington's DiseaseCompletedNCT00652457Phase 4Results posted
• Coenzyme Q10 in Huntington's Disease (HD)TerminatedNCT00608881Phase 3Results posted
• Atomoxetine and Huntington's DiseaseCompletedNCT00368849Phase 2Results posted
• Pilot Study of Minocycline in Huntington's DiseaseCompletedNCT00277355Phase 2/3Results posted
• Citalopram to Enhance Cognition in HDCompletedNCT00271596Phase 2Results posted
• Biology-Driven Cognitive Profiling in Huntington's DiseaseActive, not recruitingNCT07503743
• The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.CompletedNCT07344519Early Phase 1
• A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.Active, not recruitingNCT07339514Phase 1/2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's DiseaseActive, not recruitingNCT07246941Phase 1
• Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)Active, not recruitingNCT07213648Not applicable
• Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's DiseaseActive, not recruitingNCT06873334Phase 2/3
• Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion CarriersCompletedNCT06667414
• Longitudinal SV2A PET and MRI in Premanifest HDActive, not recruitingNCT06626412Not applicable
• Handgrip and Respiratory Dysfunction in HD Patients.CompletedNCT06585332
• Time-Restricted Eating in Huntington's Disease: A Clinical Pilot StudyCompletedNCT06490367Not applicable
• Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release TabletsCompletedNCT06474650Phase 1
• Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease PatientsCompletedNCT06469853Phase 2
• Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HDCompletedNCT06444217Not applicable
• Huntington's Disease Young Adult Study 2.0Active, not recruitingNCT06391619
• Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical ResearchCompletedNCT06343220
• An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)Active, not recruitingNCT06254482Phase 2
• Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy SubjectsCompletedNCT06216054Phase 1
• Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register StudyActive, not recruitingNCT06209515
• The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's DiseaseCompletedNCT06024265Early Phase 1
• Impact of Apathy on Caregiving in HD. Version 1Status unknownNCT05913154
• Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement DisordersCompletedNCT05769972Not applicable
• Development of the Virtual Unified Huntington's Disease Rating ScaleCompletedNCT05748288
• Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's DiseaseActive, not recruitingNCT05707663
• GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's DiseaseActive, not recruitingNCT05686551Phase 2
• A Pilot Study of Nutritional Status in Patients With Huntington's DiseaseStatus unknownNCT05668520
• Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their CaregiversActive, not recruitingNCT05596760Not applicable
• A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's DiseaseActive, not recruitingNCT05541627Phase 1/2
• Clinicopathological MRI and CSF Correlates in Huntington's Disease.Status unknownNCT05534139
• Move to Improve: Telehealth Exercise to Music for HDCompletedNCT05270681Not applicable
• Making HD Voices HeardCompletedNCT05268029
• Energy Balance in Huntington's Disease. A Multidisciplinary Study Approach for a Complex Problem (BEHD-EM)CompletedNCT05250323
• Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's DiseaseActive, not recruitingNCT05243017Phase 1/2
• A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy SubjectsCompletedNCT05238701Phase 1
• N- Homocysteinylated Huntingtin in Huntington's DiseaseStatus unknownNCT05225051Not applicable
• Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.CompletedNCT05224115
• Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's DiseaseCompletedNCT05157074Not applicable
• Complex Eye Movements in Parkinson's Disease and Related Movement DisordersCompletedNCT04925622
• Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During Rehab StayCompletedNCT04917133Not applicable
• Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's DiseaseWithdrawnNCT04885114Phase 1
• TEsting METformin Against Cognitive Decline in HDCompletedNCT04826692Phase 3
• Preparing for Prevention of Huntington's Disease (PREVENT-HD)CompletedNCT04818060
• Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington DiseaseActive, not recruitingNCT04713982Phase 2/3
• Synaptic Density and Progression of Huntington's Disease.CompletedNCT04701580Not applicable
• NIPD on cffDNA for Triplet Repeat DiseasesStatus unknownNCT04698551
• Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic MarkersCompletedNCT04630574
• Assessing the Symptomatic Benefit of Acoustic Slow Wave Enhancement in Parkinson DiseaseStatus unknownNCT04589182Not applicable
• Mitochondrial Biomarkers in Huntington's DiseaseCompletedNCT04515550
• Non-invasive Brain Stimulation in Huntington's DiseaseStatus unknownNCT04429230Not applicable
• Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot StudyCompletedNCT04421339Not applicable
• Skills of Home Helpers for a Better Quality of Life for Adults With Huntington's Disease Living at HomeStatus unknownNCT04411238
• Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HDStatus unknownNCT04406636
• Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseCompletedNCT04400331Phase 3
• Couple and Spouse Caregiver in Huntington's DiseaseTerminatedNCT04394767
• Development of Assessments for Later Stage HDStatus unknownNCT04370470
• Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HDTerminatedNCT04301726Phase 1
• Biological Sample Collection for Research and BiobankingTerminatedNCT04270604
• Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HDCompletedNCT04257513
• Deep Brain Stimulation Treatment for Chorea in Huntington's DiseaseStatus unknownNCT04244513Not applicable
• Using Wearable and Mobile Data to Diagnose and Monitor Movement DisordersStatus unknownNCT04231487
• Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.Status unknownNCT04219241Phase 2/3
• Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's DiseaseActive, not recruitingNCT04120493Phase 1/2
• Symptomatic Therapy for Patients With Huntington's DiseaseStatus unknownNCT04071639Phase 1
• Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific ProductsTerminatedNCT03886753
• iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626TerminatedNCT03810898Early Phase 1
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BCompletedNCT03787758Phase 1
• Nilotinib in Huntington's DiseaseStatus unknownNCT03764215Phase 1
• CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female SubjectsStatus unknownNCT03713892Phase 1
• FuRST 2.0 Cognitive Pre-testing - Round 2CompletedNCT03709173
• HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United StatesCompletedNCT03628235
• Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's DiseaseStatus unknownNCT03599076
• Efficacy and Safety of SOM3355 in Huntington's Disease ChoreaCompletedNCT03575676Phase 2
• Genetic Risk: Whether, When, and How to Tell AdolescentsCompletedNCT03421327
• Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease PatientsCompletedNCT03417583Not applicable
• PHysical Activity and Exercise Outcomes in Huntington's DiseaseStatus unknownNCT03344601Not applicable
• Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HDCompletedNCT03306888Phase 1/2
• Metabolomic Study in Huntington's Disease (METABO-HD)Status unknownNCT03296176Not applicable
• Decoding Presymptomatic White Matter Changes in Huntington DiseaseCompletedNCT03193099Not applicable
• Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of DysarthriaWithdrawnNCT03142217Not applicable
• Beta Testing of a New Assessment in Huntington's Disease (HD)Status unknownNCT03119246Not applicable
• NIPD on CFTC for Triplet Repeat DiseasesCompletedNCT03087526Not applicable
• Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological PathologiesTerminatedNCT03052712Not applicable
• Is Caffeine an Environmental Modifier in Huntington's Disease?CompletedNCT03034122
• Gait Analysis in Neurological DiseaseActive, not recruitingNCT02994719
• Exploring Computerised Cognitive Training for People With Huntington's DiseaseCompletedNCT02990676Not applicable
• Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion CarriersCompletedNCT02956148Early Phase 1
• Working Memory Training in Huntington's DiseaseCompletedNCT02926820Not applicable
• Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy VolunteersTerminatedNCT02907294Phase 1
• FuRST 2.0 Cognitive Pre-TestingCompletedNCT02881931
• Caregiver Burden in Huntington's DiseaseCompletedNCT02876445Not applicable
• Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)CompletedNCT02819700
• Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry ParadigmCompletedNCT02814201
• Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.CompletedNCT02750982Not applicable
• Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's DiseaseStatus unknownNCT02728115Phase 1
• Measuring Cortisol Levels in Persons With Parkinson's (PD)CompletedNCT02727270
• Dynamic Neuroimaging Biomarkers in Huntington's DiseaseCompletedNCT02639871

← Huntington Disease overview